PrimeC can significantly slow ALS progression, PARADIGM trial finds
People with amyotrophic lateral sclerosis (ALS) given PrimeC in the PARADIGM Phase 2b trial — and who did not…
Articles by Andrea Lobo, PhD
Final part of Phase 1 trial to test prosetin in ALS patients
Health Canada has cleared ProJenX to open the third part of its ongoing Phase 1 clinical trial and begin…
Blink reflex test may be biomarker to diagnose, monitor ALS: Study
A test that assesses the electrical activity associated with blinking may help speed the diagnosis of amyotrophic lateral…
ALS research center planned to open at Vanderbilt University
A neuroscientist with a specialty in amyotrophic lateral sclerosis (ALS) is joining the faculty at Vanderbilt University Medical Center…
BrainStorm, FDA to discuss plans for Phase 3b trial of NurOwn on Dec. 6
The U.S. Food and Drug Administration (FDA) soon will meet with BrainStorm Cell Therapeutics to discuss the company’s plans…
£14.5M awarded toward ALS, other neurodegenerative disease projects
A partnership between LifeArc and the UK Dementia Research Institute (UK DRI) is awarding £14.5 million (about $18.2 million)…
High uric acid levels may protect against cognitive decline in ALS
Having higher blood levels of uric acid may prevent or delay the decline in cognitive function in people with…
Top-line results of PARADIGM trial into PrimeC expected by year’s end
NeuroSense Therapeutics is planning to soon announce top-line safety and efficacy results from its PARADIGM trial, which is…
Survey offers look at life, treatment priorities of those living with ALS
People with amyotrophic lateral sclerosis (ALS) report significant changes in lifestyle after their diagnosis, but still have an acceptable…
FDA names CB03, aiming to protect neurons, an orphan drug for ALS
The U.S. Food and Drug Administration (FDA) has given orphan drug designation to CB03, Zhimeng Biopharma’s small molecule…